Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection

doi:10.19803/j.1672-8629.20230653

Abstract

Abstract: Objective To analyze the adverse drug reactions (ADR) induced by cerebroprotein hydrolysate for injection and to find out about the characteristics of such ADR so as to provide data for safe clinical use of cerebroprotein hydrolysate for injection. Methods Data on ADR of cerebroprotein hydrolysate for injection between 2011 and 2022 was collected by Qujing Food and Drug Adverse Reaction and Drug Abuse Monitoring Center. Results Most of the 319 cases of adverse reaction caused by cerebroprotein hydrolysate for injection occurred in patients over 61 years old. Adverse reaction usually occurred within 30 minutes of medication and manifested themselves in skin and appendages disorders, gastrointestinal disorders, and respiratory disorders. There were a total of 56 cases of severe ADR that were characterized by anaphylactoid reaction and anaphylactic shock. Conclusion Clinicians should be alert to ADR caused by cerebroprotein hydrolysate for injection in clinical practice, standardize clinical medication, prevent the occurrence of such serious adverse reactions as anaphylaxis.

Key words: injection, cerebroprotein hydrolysate, adverse drug reaction, rational drug use, anaphylaxis shock, anaphylactoid reaction

CLC Number:

R971
R994.11

LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.

Add to citation manager EndNote|Ris|BibTeX

URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20230653

https://www.zgywjj.com/EN/Y2024/V21/I2/195

References

[1] ZHANG TT, HU YZ.Advances in the research of cerebroprotein hydrolysate medicine with the cranial nerve diseases[J]. World Clinical Drugs(世界临床药物), 2020, 41(9): 747-751.
[2] LAI BY.Effect of cerebroprotein hydrolysate on ischemic cerebrovascular disease[J]. Heilongjiang Journal of Traditional Chinese Medicine(黑龙江中医药), 2020, 49(4): 115-116.
[3] DENG GJ.Clinical effects of cerebroprotein hydrolysate oral liquid on patients with cognitive impairment after stroke[J]. China Journal of Pharmaceutical Economics(中国药物经济学), 2019, 14(12): 63-65.
[4] LIN H, ZHOU E, HUANG BF.Clinical effect of cerebroprotein hydrolysate on patients with hypertensive intracerebral hemorrhage after evacuation of intracranial hematoma[J]. Chinese Journal of Clinical Rational Drug Use(临床合理用药), 2023, 16(10): 67-70.
[5] WANG YM, JIN YH, JIANG H.Experience in rescue and nursing care of a patient with anaphylaxis caused by cerebroprotein hydrolysate injection[J].Guide of China Medicine(中国医药指南), 2014, 12(10): 213.
[6] LIU L, SHI RY.A case of anaphylaxis caused by cerebroprotein hydrolysate for injection[J]. Gansu Medical Journal(甘肃医药), 2018, 37(2): 192.
[7] ZHANG HM, HOU JQ, ZHOU W.Two cases of anaphylaxis caused by troxerutin and cerebroprotein hydrolysate injection[J]. Herald of Medicine(医药导报), 2020, 39(2): 245-246.
[8] WANG D.A case of anaphylaxis caused by cerebroprotein hydrolysate for injection[J]. China’s Naturopathy(中国民间疗法), 2014, 22(6): 68.
[9] YPK. Package Insert of Cerebroprotein Hydrolysate Injection[EB/OL].[2023-12-07]. https://ypk.39.net/590219/manual/.
[10] EMILY M, KYAN M, THELEN VB, et al.Perinatal androgens organize sex differences in mast cells and attenuate anaphylaxis severity into adulthood[J]. Proceedings of the National Academy of Sciences, 2020, 117(38): 23751-23761.
[11] LI XL, WANG YL, ZHANG AP.Cause analysis and countermeasures of adverse drug reactions of traditional Chinese medicine injection[J]. Proceeding of Clinical Medicine(临床医药实践), 2020, 29(5): 388-390.
[12] TIAN J.Research progress on clinical application of brain protein hydrolysate[J]. Medical Innovation of China(中国医药创新), 2010, 7(2): 121-122.
[13] YE LC,MAO SZ.Research progress on pharmacological action and clinical application of brain protein hydrolysate[J]. Herald of Medicine(医药导报), 2008, 27(1): 72-73.
[14] CHEN L.Effect of cerebroprotein hydrolysate on neonatal hypoxic-ischemic encephalopathy[J]. Chinese Health Care(中华养生保健), 2021, 39(2): 36-37.
[15] ZHAO Q, XU YR, WANG XB.Analysis of clinical drug use of troxerutin and cerebroprotein hydrolysate injection[J]. Journal of China Prescription Drug(中国处方药), 2020, 18(8): 53-55.
[16] National Medical Products Administration. Notice in National Medical Products Administration on the revision of the instructions for cerebroprotein hydrolysate injections[EB/OL].(2016-11-10)[2023-06-13]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/ypshmshxdgg/20161110203201653.html.
[17] YANG YB, ZHANG ZY, WEI CH.Quality standard and adverse reactions of cerebroprotein hydrolysate preparations[J]. China Pharmacy(中国药房), 2012, 23(1): 82-84.
[18] National Health Commission of the People’s Republic of China. Circular of the General Office of the National Health Commission on the issuance of the second national catalogue of drugs for rational use[EB/OL]. (2023-01-15)[2023-12-07]. http://www.nhc.gov.cn/yzygj/s7659/202301/5b291aaae64b4e56a10f9ea910e11426.shtml.